Denmark is the first nation in Europe—and in the world—to switch all well-treated rheumatoid arthritis patients from reference infliximab (Remicade) to the biosimilar Remsima, and 1 early study suggests that the switch has been successful. Patients, however, have needed convincing.
Denmark is the first nation in Europe—and in the world—to switch all well-treated rheumatoid arthritis patients from reference infliximab (Remicade) to the biosimilar Remsima, and 1 early study suggests that the switch has been successful.
The study, published in Annals of the Rheumatic Diseases, examined the non-medical switch of 802 Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) from the reference to the biosimilar infliximab. The researchers investigated the patients’ disease activity 3 months prior to and 3 months after the switch and subsequently measured changes over time. The 403 patients with RA, 120 patients with PsA, and 279 with AxSpA had been treated with the reference infliximab for a median duration of 6.8 years (range, 4.3 to 9.5). Follow-up was conducted at 413 days (range, 339 to 442). The researchers found that disease activities were similar 3 months before and after the switch, and concluded that the switch had no negative impact on disease activity.
The results suggest that Denmark could realize a substantial cost savings in the treatment of RA by switching patients to a lower-cost, high-quality biosimilar treatment. Yet, however willing Denmark’s health system may be to make the switch from reference to biosimilar products, Danish patients have been reluctant to switch from more familiar biologics to less expensive biosimilars.
A statement provided by the European League Against Rheumatism (EULAR) says that many patients felt anxious about the national switch to biosimilars and their concerns were exacerbated by several factors:
To address these apprehensions, the Danish Rheumatism Association (DRA), a non-governmental organization with an 80,000-person membership, engaged with politicians, medical authorities, and hospital administrations in a 4-pronged plan, which ran from August 2015 through the end of 2016, and had the following objectives:
Additionally, representatives from the DRA have participated in working groups in hospitals across the nation’s regions with the objective of including the patient perspective in future national recommendations concerning biological drugs, biosimilars, and switching.
The US healthcare system differs significantly from the government-sponsored Danish system, in which patients could be made to switch treatments unless a medically justified reason prevented treatment with the biosimilar. In the United States, patients may have more say in their own treatment protocols, and may prove reluctant to switch treatments if they do not feel that biosimilars provide as much safety and efficacy as they do affordability. Manufacturers, payers, and other stakeholders seeking to drive biosimilar uptake in the United States may wish to look to the DRA’s example in advocating for and facilitating greater education and safety monitoring as a means of alleviating patient concerns.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.